Tau brain imaging in typical and atypical Alzheimer’s Disease (AD)

Tau brain imaging in typical and atypical Alzheimer’s Disease (AD) - TEPTAU

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-002223-28-FR

Enrollment

Registered

2016-11-30

Start date

2016-11-30

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's diseases

Interventions

Product Name: 7-(6-[F-18]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole Product Code: [18F]-T807 Pharmaceutical Form: Solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Age = 50 years - Native language: French - Studies level = 7 years (considering as a starting point in the first year of primary education) - Correct sensory capabilities (hearing aids accepted) to perform the tests - Affiliation to the social security system, - Informed Consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactClinical Trial Information

CHRU DE TOURS

k.chene@chu-tours.fr0033218370803

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026